VERTEX PHARMACEUTICALS INC (VRTX) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 75% based on the firm’s underlying fundamentals and the ...

Vertex Pharmaceuticals VRTX +1.22% Get Free Report has outperformed the market over the past 20 years by 10.58% on an ...

The stock's fall snapped a four-day winning streak.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

With a market cap of $114.8 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company specializing in ...

CRISPR Therapeutics stock is down more than 80% from the peak ... Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose ...

Tweedy Browne’s 13F portfolio value dropped to $1.13B, with holdings rising to 59. Click here to read more about Tweedy ...

Short interest in Vertex Pharmaceuticals Inc (NASDAQ:VRTX) decreased during the last ... to close out their positions without sending the stock sharply higher.

Stock prices may also move more quickly in this environment. Investors who anticipate trading during these times are strongly advised to use limit orders. Data is delayed at least 15 minutes.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...